Clinical Implication on Expression of HLA Class I in Breast Cancer Tissures_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LI Linqing ¹ , ZHUANG Wenxin ² , LI Pengcheng ¹ ,  SUN Xuejun. ¹

1.?The Second Department of General Surgery， The 89th Hospital of PLA， Weifang 261021， Shandong Province， China;;
2.?Medical Research Center， Weifang Medical University， Weifang 261053， Shandong Province， China;

Corresponding author：

SUN Xuejun., Email: sxj0518@sina.com

Keywords：

HLA class I; T cell immunology; Antitumor activity; Breast cancer

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To investigate the clinical implication on expression of HLA class I in breast cancer tissures.
Methods 　The expression of HLA class I in 271 patients with breast cancer that underwent radical operation was examined
by using immunohistochemically， and the correlation between the expression of HLA class I and clinicalpathological characteristics and prognosis of breast cancer was analyzed.
Results 　The b positive expression of HLA class I in breast cancer tissures was observed in 92 patients （33.9%）， the expressions of HLA class I in 179 patients （66.1%）were downregulation. The expression of HLA class I expression in breast cancer tissures was significantly associated with the axillary lymph node metastasis， TNM stage （P＜0.05）， other lymph node metastasis， and vascular invasion （P＜0.05）. The disease free survival rate of patients with positive expression of HLA class I was higher than that expression downregulation of HLA class I （P＜0.05）.
Conclusion 　The examination of HLA class I expression is useful for the prediction of tumor progression and recurrent risk of breast cancer via the antitumor immune system.

Citation： LI Linqing,ZHUANG Wenxin,LI Pengcheng,SUN Xuejun.. Clinical Implication on Expression of HLA Class I in Breast Cancer Tissures. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(10): 1132-1136. doi: Copy

1.	Cabrera T， Maleno I， Collado A， et al. Analysis of HLA class I alterations in tumors：choosing a strategy based on known patternsof underlying molecular mechanisms[J]. Tissue Antigens， 2007， 69(Suppl 1)：264-268.
2.	Nagorsen D， Thiel E. HLA typing demands for peptide-based anti-cancer vaccine[J]. Cancer Immunol Immunother， 2008， 57(12)：1903-1910.
3.	-microglobulin (beta 2m) with mouse class I major histocompati-bility antigens and its ability to support peptide binding. A comp-arison of human and mouse beta 2m[J]. Eur J Immunol， 1995， 25(6)：1609-1616.
4.	Marincola FM， Jaffee EM， Hicklin DJ， et al. Escape of human solid tumors from T-cell recognition：molecular mechanisms and functional significance[J]. Adv Immunol， 2000， 74：181-273.
5.	Tangri S， Ishioka GY， Huang X， et al. Structural features of peptideanalogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-typepeptide[J]. J Exp Med， 2001， 194(6)：833-846.
6.	Garrido F， Cabrera T， Concha A， et al. Natural history of HLA expression during tumour development[J]. Immunol Today， 1993， 14(10)：491-499.
7.	Garrido F， Ruiz-Cabello F， Cabrera T， et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours[J]. Immunol Today， 1997， 18(2)：89-95.
8.	Hicklin DJ， Marincola FM， Ferrone S. HLA class I antigen downregulation in human cancers：T-cell immunotherapy revives an old story[J]. Mol Med Today， 1999， 5(4)：178-186.
9.	Pedersen LO， Stryhn A， Holter TL， et al. The interaction of beta.
10.	Cabrera T， Angustias Fernandez M， Sierra A， et al. High frequ-ency of altered HLA class I phenotypes in invasive breast carcinomas[J]. Hum Immunol， 1996， 50(2)：127-134.
11.	Tsukahara T， Kawaguchi S， Torigoe T， et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-panHLA class I monoclonal antibody， EMR8-5[J]. Cancer Sci， 2006， 97(12)：1374-1380.
12.	Qifeng S， Bo C， Xingtao J， et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics[J]. J Thorac Cardiovasc Surg， 2011， 141(3)：808-814.
13.	Kikuchi E， Yamazaki K， Torigoe T， et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer[J]. Cancer Sci， 2007， 98(9)：1424-1430.
14.	Kitamura H， Honma I， Torigoe T， et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma[J]. J Urol， 2007， 177(4)：1269-1272.
15.	Ishigami S， Natsugoe S， Nakajo A， et al. HLA-class I expression in gastric cancer[J]. J Surg Oncol， 2008， 97(7)：605-608.
16.	Campoli M， Ferrone S. HLA antigen changes in malignant cells：epigenetic mechanisms and biologic significance[J]. Oncogene， 2008， 27(45)：5869-5885.
17.	de Kruijf EM， Sajet A， van Nes JG， et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognosticvalue for clinical outcome of early breast cancer patients[J]. J Immunol， 2010， 185(12)：7452-7459.
18.	Boomsma MF， Garssen B， Slot E， et al. Breast cancer surgery-induced immunomodulation[J]. J Surg Oncol， 2010， 102(6)：640-648.
19.	de Kruijf EM， van Nes JG， Sajet A， et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer[J]. Clin Cancer Res， 2010， 16(4)：1272-1280.
20.	Lavado-Valenzuela R， Benavides M， Carabantes F， et al. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer[J]. Tissue Antigens， 2009， 74(1)：46-49.
21.	Torigoe T， Asanuma E， Tamura Y， et al. Establishment of a mono-clonal anti-pan HLA class I antibody suitable for immunostainingof formalin-fixed tissue：unusually high frequency of down-regulation in breast cancer tissues[J]. Pathol Int， 2012， 62(5)：303-308.
22.	Cordon-Cardo C， Fuks Z， Drobnjak M， et al. Expression of HLA-A， B， C antigens on primary and metastatic tumor cell populations of human carcinomas[J]. Cancer Res， 1991， 51(23 Pt 1)：6372-6380.
23.	Madjd Z， Spendlove I， Pinder SE， et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer[J]. Int J Cancer， 2005， 117(2)：248-255.
24.	Sato N， Hirohashi Y， Tsukahara T， et al. Molecular pathological approaches to human tumor immunology[J]. Pathology International， 2009， 59(4)：205-217.
25.	Mizukami Y， Kono K， Maruyama T， et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer， 2008， 99(9)：1462-1467.
26.	Pistillo MP， Nicolò G， Salvi S， et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues[J]. Hum Immunol， 2000， 61(4)：397-407.
27.	Zia A， Schildberg FW， Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients[J]. Int J Cancer， 2001， 93(4)：566-570.

1. Cabrera T， Maleno I， Collado A， et al. Analysis of HLA class I alterations in tumors：choosing a strategy based on known patternsof underlying molecular mechanisms[J]. Tissue Antigens， 2007， 69(Suppl 1)：264-268.
2. Nagorsen D， Thiel E. HLA typing demands for peptide-based anti-cancer vaccine[J]. Cancer Immunol Immunother， 2008， 57(12)：1903-1910.
3. -microglobulin (beta 2m) with mouse class I major histocompati-bility antigens and its ability to support peptide binding. A comp-arison of human and mouse beta 2m[J]. Eur J Immunol， 1995， 25(6)：1609-1616.
4. Marincola FM， Jaffee EM， Hicklin DJ， et al. Escape of human solid tumors from T-cell recognition：molecular mechanisms and functional significance[J]. Adv Immunol， 2000， 74：181-273.
5. Tangri S， Ishioka GY， Huang X， et al. Structural features of peptideanalogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-typepeptide[J]. J Exp Med， 2001， 194(6)：833-846.
6. Garrido F， Cabrera T， Concha A， et al. Natural history of HLA expression during tumour development[J]. Immunol Today， 1993， 14(10)：491-499.
7. Garrido F， Ruiz-Cabello F， Cabrera T， et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours[J]. Immunol Today， 1997， 18(2)：89-95.
8. Hicklin DJ， Marincola FM， Ferrone S. HLA class I antigen downregulation in human cancers：T-cell immunotherapy revives an old story[J]. Mol Med Today， 1999， 5(4)：178-186.
9. Pedersen LO， Stryhn A， Holter TL， et al. The interaction of beta.
10. Cabrera T， Angustias Fernandez M， Sierra A， et al. High frequ-ency of altered HLA class I phenotypes in invasive breast carcinomas[J]. Hum Immunol， 1996， 50(2)：127-134.
11. Tsukahara T， Kawaguchi S， Torigoe T， et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-panHLA class I monoclonal antibody， EMR8-5[J]. Cancer Sci， 2006， 97(12)：1374-1380.
12. Qifeng S， Bo C， Xingtao J， et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics[J]. J Thorac Cardiovasc Surg， 2011， 141(3)：808-814.
13. Kikuchi E， Yamazaki K， Torigoe T， et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer[J]. Cancer Sci， 2007， 98(9)：1424-1430.
14. Kitamura H， Honma I， Torigoe T， et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma[J]. J Urol， 2007， 177(4)：1269-1272.
15. Ishigami S， Natsugoe S， Nakajo A， et al. HLA-class I expression in gastric cancer[J]. J Surg Oncol， 2008， 97(7)：605-608.
16. Campoli M， Ferrone S. HLA antigen changes in malignant cells：epigenetic mechanisms and biologic significance[J]. Oncogene， 2008， 27(45)：5869-5885.
17. de Kruijf EM， Sajet A， van Nes JG， et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognosticvalue for clinical outcome of early breast cancer patients[J]. J Immunol， 2010， 185(12)：7452-7459.
18. Boomsma MF， Garssen B， Slot E， et al. Breast cancer surgery-induced immunomodulation[J]. J Surg Oncol， 2010， 102(6)：640-648.
19. de Kruijf EM， van Nes JG， Sajet A， et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer[J]. Clin Cancer Res， 2010， 16(4)：1272-1280.
20. Lavado-Valenzuela R， Benavides M， Carabantes F， et al. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer[J]. Tissue Antigens， 2009， 74(1)：46-49.
21. Torigoe T， Asanuma E， Tamura Y， et al. Establishment of a mono-clonal anti-pan HLA class I antibody suitable for immunostainingof formalin-fixed tissue：unusually high frequency of down-regulation in breast cancer tissues[J]. Pathol Int， 2012， 62(5)：303-308.
22. Cordon-Cardo C， Fuks Z， Drobnjak M， et al. Expression of HLA-A， B， C antigens on primary and metastatic tumor cell populations of human carcinomas[J]. Cancer Res， 1991， 51(23 Pt 1)：6372-6380.
23. Madjd Z， Spendlove I， Pinder SE， et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer[J]. Int J Cancer， 2005， 117(2)：248-255.
24. Sato N， Hirohashi Y， Tsukahara T， et al. Molecular pathological approaches to human tumor immunology[J]. Pathology International， 2009， 59(4)：205-217.
25. Mizukami Y， Kono K， Maruyama T， et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer， 2008， 99(9)：1462-1467.
26. Pistillo MP， Nicolò G， Salvi S， et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues[J]. Hum Immunol， 2000， 61(4)：397-407.
27. Zia A， Schildberg FW， Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients[J]. Int J Cancer， 2001， 93(4)：566-570.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Implication on Expression of HLA Class I in Breast Cancer Tissures

Abstract Full text Figures/Tables Video References Cited by

Format

Content